Awards

Patents

1. Authors: Lizasoain I, Moro MA, Hurtado O, Pradillo J. Tittle: Composición farmacéutica para el tratamiento de las enfermedades cerebrovasculares. Spanish Register number: P201101263. Date: 2011. Center: Universidad Complutense de Madrid. Spanish Patent.

2. Authors: Moro MA, Lizasoain I, Sánchez-Prieto J, Torres M, Godino MC, Sobrado M, González VM, Vivancos J. Tittle: Use of a composition in the preparation of a dialysis solution for the treatment of cerebrovascular diseases by means of peritoneal dialysis. Spanish Register number: P201100829. Date: 2014. Center: Universidad Complutense Madrid. European Patent. PCT application number: PCT/ES2012/000195.

3. Inventors: Lizasoain I, González V, Fernández G, Moro MA, Martín E, Moraga A. Tittle: Aptamers specific for TLR4 and uses thereof. Spanish Register number: P201430955. Date: 2015. Center: Universidad Complutense Madrid, Aptus Biotech SL. European Patent. PCT application number: PCT/EP2015/064277.

4. Inventors: Boscá L, De Castro F, Fernández B, Hernández-Jiménez M, Lizasoain I, Moro MA, Piñeiro D, Pérez D, Segarra D, Zarabozo ME, Zaragoza C. Title: Treatment of TLR4 mediated diseases and conditions with aptamers targeting TLR-4. Patent No.: WO2020230108A1. PCT Applicación No.: PCT/IB2020/054654. Application: 2020-05-16. Date: 2020-11-19.

5. Inventors: Di G, Lizasoain I. Title: A stereotaxic brain fixation table for anesthetized mouse. CNIPA Applicatio No.: ZL202220116340.0. Certificate No.: 17315558 . Application: 2022-01-17. Date: 2022-08-30.

Collaborative Projects

PROFIT CIT-090100-2005-15
PROFIT CIT-090100-2007-43
PROFIT CIT-090000-2008-11
RTC-2015-3741-1
RTC-2017-6283-1

As a result of our collaborative work with the Ministry of Industry and different companies, the Neurovascular Research Unit participates together with IRYCIS and the company Aptus Biotech in a 2.7M euro investment round thanks to two investment funds (Caixa Capital Risc and Inveready) to complete the preclinical phase and enter the clinical trial phases I and II of ApTOLL (own design product that is patented).

The international patents (see patents) have been the result of the development of an aptamer (publication: Mol Ther. 2018) and have allowed us to obtain different public and private contracts that have allowed us to complete the preclinical phase and enter Phase I and II clinical trials of ApTOLL (Phase I trial: NCT04742062; and Phase Ib/IIa trial: NCT04734548).